Promising Ag(I) complexes with N-acylhydrazones from aromatic aldehydes and isoniazid against multidrug resistance in tuberculosis

Autor(es)

dos Santos, Paulo Victor P. ^[1] ; Ribeiro, Camila M. ^[2] ; Pavan, Fernando R. ^[2] ; Corbi, Pedro P. ^[3] ; Bergamini, Fernando R. G. ^{[3, 4]} ; Carvalho, Marcos A. ^{[3, 5]} ; D'Oliveria, Kaique A. ^[1] ; Cuin, Alexandre ^[1]

Afiliação do(s) autor(es)

^[1] Fed Univ Juiz de Fora UFJF, Inst Exact Sci, Dept Chem, LQBin Lab BioInorgan Chem, BR-36036330 Juiz De Fora, MG - Brazil

^[2] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, TB Res Lab Araraquara, Araraquara, SP - Brazil

^[3] Univ Campinas UNICAMP, Inst Chem, BR-13083970 Campinas, SP - Brazil

^[4] Fed Univ Uberlandia UFU, Inst Chem, Lab Synth Bioinspired Mol, Uberlandia, MG - Brazil

^[5] Fed Univ Mato Grosso UFMT, Dept Chem, BR-78060900 Cuiaba, MT - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Molecular Structure; v. 1234, JUN 15 2021.
• Citações Web of Science: 0

Resumo

In the present work, synthesis, characterization and antitubercular assays of N-acylhydrazones derivatives and their corresponding silver(I) complexes are described. The compounds were characterized by elemental analysis, IR and NMR spectroscopic measurements, molar conductivity assays and powder diffraction X ray studies. Some of the synthesized compounds have shown minimum inhibitory concentration (MIC90) values against M. tuberculosis H37Rv (ATCC 27294) lower than 0.098 mu g/mL, while the cytotoxic activity assays over MRC-5 cells reveled that all compounds present selectivity indexes higher than 27. Furthermore, N-acylhydrazones compounds showed promising activities even against multidrug-resistant clinical strains of M. tuberculosis. (C) 2021 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 18/12062-4 - Síntese, caracterização e estudos de interação com biomoléculas de complexos metálicos contendo ligantes biologicamente ativos: uma estratégia na preparação de novos agentes com atividades antibacterianas e antivirais
• Beneficiário: Pedro Paulo Corbi
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/00163-0 - Desenvolvimento e busca de novos antimicrobianos contra Tuberculose: da triagem a estudos pré-clínicos in vivo
• Beneficiário: Fernando Rogério Pavan
• Modalidade de apoio: Auxílio à Pesquisa - Regular